1. Neoadjuvant systemic therapy in geriatric breast cancer patients: a National Cancer Database (NCDB) analysis

   • Lauren Brown
   • Samer A. Naffouje
   • M. Catherine Lee

   Review 08 October 2022 Pages: 441 - 451

   

2. Contemporary evaluation of estrogen receptor and progesterone receptor expression in breast cancer-associated stroma

   • Gustavo A. Moreno
   • Mariel I. Molina
   • Julie M. Jorns

   Preclinical study 08 October 2022 Pages: 453 - 461

   

3. Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center

   • Saba Shafi
   • Yan Hu
   • Zaibo Li

   Preclinical study 19 October 2022 Pages: 463 - 469

   

4. Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation

   • H. Vihervuori
   • K. Korpinen
   • P. Kronqvist

   Preclinical study Open access 19 October 2022 Pages: 471 - 482

   

5. PIK3CA-mutations in breast cancer

   • Kristin Reinhardt
   • Kathrin Stückrath
   • Martina Vetter

   Preclinical study Open access 24 October 2022 Pages: 483 - 493

   

6. Intrinsic subtypes in Ethiopian breast cancer patient

   • Zelalem Desalegn
   • Meron Yohannes
   • Martina Vetter

   Preclinical study Open access 25 October 2022 Pages: 495 - 504

   

7. Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer

   • Olga Lobanova
   • Nataliia Medvedieva
   • Natalia Gorovenko

   Preclinical study 25 October 2022 Pages: 505 - 515

   

8. High-risk lesions in the breast diagnosed by MRI-guided core biopsy: upgrade rates and features associated with malignancy

   • Eumee Cha
   • Emily B. Ambinder
   • Kelly S. Myers

   Clinical trial 15 October 2022 Pages: 517 - 525

   

9. The effect of delay of excisional biopsy on upstage rate for atypical ductal hyperplasia, flat epithelial atypia, intraductal papilloma, and radial scar

   • Jesse Casaubon
   • Shiva Niakan
   • Holly Mason

   Clinical trial 01 October 2022 Pages: 527 - 534

   

10. Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer

    • Neha Verma
    • Amanda L. Blackford
    • Karen Lisa Smith

    Clinical trial 05 October 2022 Pages: 535 - 547

    

11. Patient-centered dosing: oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)

    • Anne L. Loeser
    • Lucy Gao
    • Maryam Lustberg

    Clinical trial 06 October 2022 Pages: 549 - 563

    

12. Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age

    • Austin D. Williams
    • Kate R. Pawloski
    • Mahmoud El-Tamer

    Clinical trial 21 October 2022 Pages: 565 - 570

    

13. HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane

    • Paula R. Pohlmann
    • Deena Graham
    • Sandra M. Swain

    Clinical trial Open access 25 October 2022 Pages: 571 - 581

    

14. Patterns of breast cancer second recurrences in patients after mastectomy

    • Geok Hoon Lim
    • Veronica Siton Alcantara
    • Qing Ting Tan

    Clinical trial 26 October 2022 Pages: 583 - 589

15. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors

    • Annemiek van Ommen-Nijhof
    • Judy N. Jacobse
    • Gabe S. Sonke

    Epidemiology 01 October 2022 Pages: 591 - 602

    

16. Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis

    • Jeanna Wallenta Law
    • Alicyn Campbell
    • Henry G. Kaplan

    Epidemiology Open access 06 October 2022 Pages: 603 - 611

    

17. Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study

    • Qiufan Zheng
    • Hanjia Luo
    • Shusen Wang

    Epidemiology 07 October 2022 Pages: 613 - 622

    

18. Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors

    • Rachel A. Freedman
    • Naomi Y. Ko
    • Nancy L. Keating

    Epidemiology 11 October 2022 Pages: 623 - 633

    

19. Prognosis and effectiveness of chemotherapy for medullary breast carcinoma

    • Tomohiko Aihara
    • Hiraku Kumamaru
    • Hiromitsu Jinno

    Epidemiology 23 October 2022 Pages: 635 - 645

    

20. A population health assessment of screening mammography on breast cancer mortality in North Carolina

    • Ashley E. Burch
    • William D. Irish
    • Jan H. Wong

    Epidemiology 26 October 2022 Pages: 647 - 656

    

21. Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction

    • Hope M. Guzzo
    • Stephanie A. Valente
    • Zahraa Al-Hilli

    Original Laboratory Investigation 14 October 2022 Pages: 657 - 664

    

22. Retraction Note to: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression

    • Zhongxing Liang
    • Xuehai Bian
    • Hyunsuk Shim

    Retraction Note 23 October 2022 Pages: 665 - 665